Trio of gene editing programs marks Vertex’s last additions from fruitful CRISPR deal

Vertex has opted in to three programs discovered under its 2015 deal with CRISPR Therapeutics, spending $30 million up front to gain exclusive, worldwide rights to develop gene

Read the full 285 word article

User Sign In